Evidence map›Paper›PMID 35762854›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2023

Alterations of the Primary Cilia Gene SPAG17 and SOX9 Locus Noncoding RNAs Identified by RNA-Sequencing Analysis in Patients With Systemic Sclerosis.

Elisha D O Roberson, Mary Carns, Li Cao, Kathleen Aren, Isaac A Goldberg, David J Morales-Heil, Benjamin D Korman, John P Atkinson, John Varga

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. The Role of SOX9 in IGF-II-Mediated Pulmonary Fibrosis.International journal of molecular sciences · 2023
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elisha D O RobersonDepartment of Medicine, Division of Rheumatology, and Department of Genetics, Washington University, St. Louis, Missouri.ORCID 0000-0001-5921-2399
Mary CarnsScleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Li CaoDepartment of Medicine, Division of Rheumatology, Washington University, St. Louis, Missouri.
Kathleen ArenScleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Isaac A GoldbergScleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-7178-9729
David J Morales-HeilDepartment of Medicine, Division of Rheumatology, Washington University, St. Louis, Missouri.
Benjamin D KormanScleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-4873-2628
John P AtkinsonDepartment of Medicine, Division of Rheumatology, Washington University, St. Louis, Missouri.ORCID 0000-0002-2514-3441
John VargaScleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, and Department of Internal Medicine, Division of Rheumatology University of Michigan, Ann Arbor.
Northwestern University · USWashington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1)UL1TR000150 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LLOYD-JONES, DONALD M · 2012 to 2013
$10.1M
Viral Discovery in Rheumatoid ArthritisP30AR048335 · NIAMS · WASHINGTON UNIVERSITY · PI WEIHL, CONRAD C · 2001 to 2015
$8.9M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6M
TRAINING IN THE IMMUNOLOGY OF RHEUMATIC DISEASEST32AR007279 · NIAMS · WASHINGTON UNIVERSITY · PI Megan Anne Cooper, Deborah J Lenschow · 1986 to 2026
$6.0M
GPU COMPUTING RESOURCE TO ENABLE INNOVATION IN IMAGING AND NETWORK BIOLOGYS10OD018091 · OD · WASHINGTON UNIVERSITY · PI PAPPU, ROHIT V, PRIOR, FRED WILLIAM · 2014 to 2014
$598k
NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NIAMS NIH HHS P30 AR048335NIAMS NIH HHS P30 AR073752NIAMS NIH HHS T32 AR007279NIH HHS P30-AR048335NIH HHS P30-AR073752NIH HHS P30-CA91842NIH HHS S10 OD018091NIH HHS S10-OD018091NIH HHS UL1-TR000150NIH HHS UL1-TR000448
6 · The paper itself

Abstract

objectiveSystemic sclerosis (SSc) is characterized by immune activation, vasculopathy, and unresolving fibrosis in the skin, lungs, and other organs. We performed RNA-sequencing analysis on skin biopsy samples and peripheral blood mononuclear cells (PBMCs) from SSc patients and unaffected controls to better understand the pathogenesis of SSc.

methodsWe analyzed these data 1) to test for case/control differences and 2) to identify genes whose expression levels correlate with SSc severity as measured by local skin score, modified Rodnan skin thickness score (MRSS), forced vital capacity (FVC), or diffusing capacity for carbon monoxide (DLco).

resultsWe found that PBMCs from SSc patients showed a strong type I interferon signature. This signal was found to be replicated in the skin, with additional signals for increased extracellular matrix (ECM) genes, classical complement pathway activation, and the presence of B cells. Notably, we observed a marked decrease in the expression of SPAG17, a cilia component, in SSc skin. We identified genes that correlated with the MRSS, DLco, and FVC in SSc PBMCs and skin using weighted gene coexpression network analysis. These genes were largely distinct from the case/control differentially expressed genes. In PBMCs, type I interferon signatures negatively correlated with the DLco. In SSc skin, ECM gene expression positively correlated with the MRSS. Network analysis of SSc skin genes that correlated with clinical features identified the noncoding RNAs SOX9-AS1 and ROCR, both near the SOX9 locus, as highly connected, "hub-like" genes in the network.

conclusionThese results identify noncoding RNAs and SPAG17 as novel factors potentially implicated in the pathogenesis of SSc.

Indexed as

Microtubule ProteinsScleroderma, SystemicSOX9 Transcription FactorCiliaHumansInterferon Type ILeukocytes, MononuclearRNA, UntranslatedSkinInterferon Type IMicrotubule ProteinsRNA, UntranslatedSOX9 protein, humanSOX9 Transcription FactorSPAG17 protein, human

Identifiers

PMID35762854
PMCPMC10445493
OpenAlexW4283647167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.